Optical Coherence Tomography Angiography Features of Subretinal Fibrosis in Age-Related Macular Degeneration

Mière, Alexandra; Semoun, Oudy; Cohen, Salomon Y.; Ameen, Ala El; Srour, Mayer; Jung, Camille; Oubraham, Hassiba; Querques, Giuseppe; Souied, Eric H.

doi:10.1097/iae.0000000000000819

Cited by 90 publications

(70 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…OCT-A allows the clinician to visualise CNV non-invasively, but currently does not give information about the activity status of the neovascularisation 22–24. Recent studies have evaluated the features of CNV on OCT-A showing vascular patterns and tried to correlate these features with active and inactive fibrotic neovascularisation 25. Lupidi et al 26 showed high sensitivity and specificity of CNV detection on OCT-A in cases of AFVD.…”

Section: Discussionmentioning

confidence: 99%

Optical coherence tomography angiography in adult-onset foveomacular vitelliform dystrophy

et al. 2016

Self Cite

View full text Add to dashboard Cite

In patients with AFVD, OCT-A showed vascular network rarefaction with less blood vessels at the superficial and deep capillary plexuses, and the choriocapillaris layer. These vascular abnormalities may play a role in the pathogenesis or simply represent a consequence of material accumulation and reabsorption in AFVD. In two cases, the conventional imaging did not show clearly the neovascularisation due to masking effect of the subretinal vitelliform material, while OCT-A showed distinctly the CNV.

show abstract

Section: Discussionmentioning

confidence: 99%

Optical coherence tomography angiography in adult-onset foveomacular vitelliform dystrophy

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Anti-VEGF molecules induce the blockage of pathologic vessel growth through inhibition of the migration and proliferation of endothelial cells. Anti-VEGF resistance might trigger the connective tissue deposition and the consequent scar formation [41]. …”

Section: Discussionmentioning

confidence: 99%

Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia

et al. 2017

Self Cite

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate the 9-year outcome of ranibizumab monotherapy for myopic choroidal neovascularization (mCNV). Methods: This was a retrospective, nonrandomized, multicentric study to evaluate the long-term outcomes of mCNV treated with ranibizumab monotherapy for at least 9 years according to a strict pro re nata regimen. Results: Seventeen eyes of 17 patients (12 women, mean age 57.9 ± 7.7 years) were included. The mean follow-up period was 112.4 ± 3.9 months (range 108–120). The mean difference in best-corrected visual acuity (BCVA) from baseline to the last follow-up was +1.2 ± 15.6 ETDRS letters (p = 0.004, between initial vs. 12 and 24 months). The mean total number of intravitreal injections for each patient was 1.24 ± 1.70 per year (range 2–25). No systemic adverse reactions related to the drug treatment were detected during the 9-year follow-up period. Conclusions: Long-term ranibizumab monotherapy treatment induces unchanged or better BCVA compared to baseline after a 9-year treatment in almost all eyes.

show abstract

“…Anti-VEGF-Verbindungen bewirken eine Blockade des pathologischen Gefäßwachstums, indem sie die Migration und Proliferation der Endothelzellen hemmen. Eine Anti-VEGF-Resistenz kann zur Ablagerung von Bindegewebe mit anschließender Narbenbildung führen [41]. …”

Section: Diskussionunclassified

Neun-Jahres-Ergebnisse zur Ranibizumab-Monotherapie der choroidalen Neovaskularisation infolge pathologischer Myopie

et al. 2018

Self Cite

View full text Add to dashboard Cite

Zweck: Mit der vorliegenden Studie sollten die 9-Jahres-Ergebnisse der Behandlung der myopen choroidalen Neovaskularisation (mCNV) mit Ranibizumab als Monotherapie beurteilt werden. Methoden: Es handelt sich um eine retrospektive, nicht randomisierte Multicenterstudie zur Beurteilung der Langzeitergebnisse einer mindestens 9-jährigen Behandlung der mCNV mit Ranibizumab als Monotherapie gemäß einem streng bedarfsbasierten Therapieschema. Ergebnisse: In die Studie wurden 17 Augen von 17 Patienten (12 Frauen; Durchschnittsalter 57,9 ± 7,7 Jahre) eingeschlossen. Die mittlere Nachbeobachtungsdauer betrug 112,4 ± 3,9 Monate (Spanne: 108-120). Die mittlere Differenz in der bestkorrigierten Sehschärfe (BCVA) zwischen dem Ausgangswert und der letzten Nachuntersuchung lag bei +1,2 ± 15,6 ETDRS (Early Treatment for Diabetic Retinopathy Study)-Buchstaben (p = 0,004, Ausgangswert vs. 12 und 24 Monate). Die mittlere Gesamtzahl intravitrealer Injektionen bei jedem Patienten betrug 1,24 ± 1,70 pro Jahr (Spanne: 2-25). Während der 9-jährigen Nachbeobachtung wurden keine systemischen Nebenwirkungen im Zusammenhang mit der Arzneimitteltherapie beobachtet. Schlussfolgerungen: Die Langzeit-Monotherapie mit Ranibizumab bewirkt nach 9-jähriger Behandlung bei fast allen Augen eine gegenüber Studienbeginn unveränderte oder verbesserte BCVA. Übersetzung aus Ophthalmologica 2018;239:133-142 (DOI: 10.1159/000485112)

show abstract

Optical Coherence Tomography Angiography Features of Subretinal Fibrosis in Age-Related Macular Degeneration

Cited by 90 publications

References 23 publications

Optical coherence tomography angiography in adult-onset foveomacular vitelliform dystrophy

Optical coherence tomography angiography in adult-onset foveomacular vitelliform dystrophy

Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia

Neun-Jahres-Ergebnisse zur Ranibizumab-Monotherapie der choroidalen Neovaskularisation infolge pathologischer Myopie

Contact Info

Product

Resources

About